ES2175663T3 - Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. - Google Patents

Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.

Info

Publication number
ES2175663T3
ES2175663T3 ES98904121T ES98904121T ES2175663T3 ES 2175663 T3 ES2175663 T3 ES 2175663T3 ES 98904121 T ES98904121 T ES 98904121T ES 98904121 T ES98904121 T ES 98904121T ES 2175663 T3 ES2175663 T3 ES 2175663T3
Authority
ES
Spain
Prior art keywords
treatment
oral administration
miltephosine
leshmaniasis
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98904121T
Other languages
English (en)
Inventor
Jurgen Engel
Werner Sarlikiotis
Thomas Klenner
Peter Hilgard
Dieter Sauerbier
Eckhard Milsmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeterna Zentaris GmbH
Original Assignee
Zentaris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris AG filed Critical Zentaris AG
Application granted granted Critical
Publication of ES2175663T3 publication Critical patent/ES2175663T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilización de miltefosina para la preparación de un medicamento para el tratamiento de la leishmaniasis en la especie humana por administración oral, por la que se administra oralmente una dosis diaria total en el intervalo de 10 a 250 mg del i.a. (ingrediente activo) miltefosina durante un período de tiempo de 2 a 6 semanas.
ES98904121T 1998-01-22 1998-01-22 Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. Expired - Lifetime ES2175663T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/000345 WO1999037289A1 (en) 1998-01-22 1998-01-22 Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis

Publications (1)

Publication Number Publication Date
ES2175663T3 true ES2175663T3 (es) 2002-11-16

Family

ID=8166843

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98904121T Expired - Lifetime ES2175663T3 (es) 1998-01-22 1998-01-22 Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.

Country Status (24)

Country Link
US (1) US6544551B1 (es)
EP (1) EP1051159B1 (es)
JP (1) JP2002501015A (es)
KR (1) KR100517399B1 (es)
CN (1) CN100413492C (es)
AT (1) ATE215817T1 (es)
AU (1) AU756805B2 (es)
BR (1) BR9814772A (es)
CA (1) CA2318260C (es)
CZ (1) CZ299229B6 (es)
DE (1) DE69804865T2 (es)
DK (1) DK1051159T3 (es)
ES (1) ES2175663T3 (es)
HU (1) HUP0004363A3 (es)
IL (1) IL136196A (es)
NO (1) NO20003674D0 (es)
NZ (1) NZ505648A (es)
PL (1) PL189654B1 (es)
PT (1) PT1051159E (es)
SI (1) SI1051159T1 (es)
SK (1) SK284839B6 (es)
TR (1) TR200001717T2 (es)
UA (1) UA68372C2 (es)
WO (1) WO1999037289A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10203195A1 (de) * 2002-01-25 2003-08-07 Zentaris Ag Verwendung von Alkylphosphocholinen in der Präventivbehandlung von Protozoenerkrankungen
US7887817B2 (en) * 2002-01-25 2011-02-15 Aeterna Zentaris Gmbh Process for preventing protozoal diseases
AU2002346284A1 (en) * 2002-04-26 2003-11-10 Rudolf Perl Pharmaceutical compositions of phospholipid derivatives
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
JP2005535688A (ja) 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用
WO2005023241A1 (en) 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
SI2801354T1 (sl) 2004-10-08 2017-07-31 Forward Pharma A/S Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
US8703179B2 (en) 2006-05-11 2014-04-22 Kimberly-Clark Worldwide, Inc. Mucosal formulation
WO2010020276A1 (en) * 2008-08-19 2010-02-25 Orphanidis Pharma Research Gmbh Treatment of coccidian parasites
MX2011011596A (es) 2010-03-31 2012-02-01 Keryx Biopharmaceuticals Inc Perifosina y capecitabina como un tratamiento combinado para cancer.
CA2818194A1 (en) 2010-11-22 2012-05-31 Dafra Pharma Research&Development Bvba Solid dosage forms of oleyl phosphocholine
EP3616701A1 (en) 2011-06-24 2020-03-04 GRI Bio, Inc. Prevention and treatment of inflammatory conditions
WO2014166941A1 (en) * 2013-04-08 2014-10-16 Academisch Medisch Centrum Miltefosin or perifosin for use in the treatment of ibd
CA3018828C (en) 2014-09-17 2021-05-11 Steerlife India Private Limited Effervescent composition and method of making it
CN104473941A (zh) * 2014-12-20 2015-04-01 长沙佰顺生物科技有限公司 一种含有米替福新的药物制剂及其制备方法
WO2017098481A1 (en) 2015-12-12 2017-06-15 Steerlife India Private Limited Effervescent compositions of metformin and processes for preparation thereof
ES2989158T3 (es) * 2019-04-12 2024-11-25 Oblita Therapeutics Bvba Formulaciones de dosificación en comprimidos de oleil fosfocolina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE888444C (de) * 1951-11-10 1953-08-31 Benckiser Gmbh Joh A Verfahren zum Tablettieren von hygroskopischen Praeparaten
IE59778B1 (en) * 1985-12-04 1994-04-06 Max Planck Gesellschaft Medicament with anti-tumour action containing hexadecylphosphocholine
US4762658A (en) * 1986-10-08 1988-08-09 Central Soya Company, Inc. Method of tableting of de-oiled phosphatides (lecithin)
EP0916343A1 (de) * 1989-09-27 1999-05-19 ASTA Medica Aktiengesellschaft Verwendung von Alkylphosphorsäure-Verbindungen zur Bekämpfung von Psoriasis-Erkrankungen
US5290769A (en) * 1989-09-27 1994-03-01 Asta Pharma Aktiengesellschaft Use of hexadecylphosphocholine for the treatment of psoriasis
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis

Also Published As

Publication number Publication date
CZ299229B6 (cs) 2008-05-21
NO20003674L (no) 2000-07-18
AU756805B2 (en) 2003-01-23
HUP0004363A3 (en) 2002-12-28
SK284839B6 (sk) 2005-12-01
IL136196A (en) 2004-07-25
PT1051159E (pt) 2002-09-30
AU6212198A (en) 1999-08-09
DK1051159T3 (da) 2002-08-05
NO20003674D0 (no) 2000-07-18
KR20010034311A (ko) 2001-04-25
CN100413492C (zh) 2008-08-27
TR200001717T2 (tr) 2000-11-21
SK9862000A3 (en) 2000-11-07
NZ505648A (en) 2002-10-25
HUP0004363A2 (hu) 2001-04-28
BR9814772A (pt) 2000-10-24
CN1283111A (zh) 2001-02-07
EP1051159A1 (en) 2000-11-15
CZ20002596A3 (cs) 2000-10-11
PL342838A1 (en) 2001-07-16
DE69804865T2 (de) 2002-11-07
JP2002501015A (ja) 2002-01-15
IL136196A0 (en) 2001-05-20
KR100517399B1 (ko) 2005-09-28
EP1051159B1 (en) 2002-04-10
CA2318260A1 (en) 1999-07-29
PL189654B1 (pl) 2005-09-30
SI1051159T1 (en) 2002-10-31
WO1999037289A1 (en) 1999-07-29
UA68372C2 (en) 2004-08-16
ATE215817T1 (de) 2002-04-15
US6544551B1 (en) 2003-04-08
DE69804865D1 (de) 2002-05-16
CA2318260C (en) 2006-11-21

Similar Documents

Publication Publication Date Title
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CR6458A (es) Composiciones de valdecoxib
BR0015188A (pt) Composições farmacêuticas
MX9700081A (es) Composiciones farmaceuticas de tacrina.
KR960700708A (ko) 3,4-디아릴크로만을 이용한 뼈 손실의 억제방법(methdos for inhibiting bone loss with 3,4-diarylchroman)
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
CZ289643B6 (cs) Lék pro léčbu bolesti v krku obsahující flurbiprofen
EP1444984B1 (en) Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
NO20055880L (no) Memantin orale doseringsformer
SE9901573D0 (sv) New compounds
BR0114100A (pt) Formulações de liberação controlada para administração oral
KR970061244A (ko) 치매 치료용 약학 조성물
ES2171440T3 (es) Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal.
KR970025615A (ko) 암 전이 억제제
RU2010109359A (ru) Азитромицин для лечения кожных заболеваний
CO5580741A2 (es) Composicion farmaceutica que comprende un agonista de receptor de 5ht1
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
MXPA03003994A (es) Composiciones de metformina de liberacion controlada.
BR0014593A (pt) Unidade de dosagem para administração peroral
ES2078838A1 (es) Procedimiento para preparar una composicion a base de clozapina.
JPH0489428A (ja) 多形核白血球活性化剤
AR042153A1 (es) Uso de los compuestos 2,5- dihidroxibencenosulfonicos para la fabricacion de un medicamento

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1051159

Country of ref document: ES